Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease

Article ID	Journal	Published Year	Pages	File Type
4168541	The Journal of Pediatrics	2008	12 Pages	PDF

Abstract

Both infliximab and a second IVIG infusion were safe and well tolerated in the subjects with KD who were resistant to standard IVIG treatment. The optimal management of patients resistant to IVIG remains to be determined.

Keywords

TNF sTNFR SAE IVIg RCA IgG ASA ALT AUC Aspirin Alanine aminotransferase immunoglobulin G interleukin Intravenous immunoglobulin Kawasaki disease clearance Intravenous RCA, right coronary artery adverse event severe adverse event tumor necrosis factor LAD area under the curve C-reactive protein CRP left anterior descending coronary artery

Related Topics

Health Sciences Medicine and Dentistry Perinatology, Pediatrics and Child Health

Preview

Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease

Authors

Jane C. MD, Brookie M. PharmD, MAS, Asuncion MD, Lynn MD, David E. MD, Hasan S. MD, Marian E. MD, Mary Anne MD, Basim I. MD, David J. MD, James D. MD, Edmund V. PharmD, Monica L. BS, Khalid BS, Gregory F. MD, Octavio MD,